Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and
pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic
renal cell carcinoma progressing on Sunitinib Malate.